• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JAMA Netw Open . Estimated Effectiveness of Influenza Vaccines in Preventing Secondary Infections in Households

tetano

Editor, Senior Moderator
JAMA Netw Open


. 2024 Nov 4;7(11):e2446814.
doi: 10.1001/jamanetworkopen.2024.46814. Estimated Effectiveness of Influenza Vaccines in Preventing Secondary Infections in Households

Carlos G Grijalva[SUP] 1 [/SUP], Huong Q Nguyen[SUP] 2 [/SUP], Yuwei Zhu[SUP] 1 [/SUP], Alexandra M Mellis[SUP] 3 [/SUP], Trey McGonigle[SUP] 1 [/SUP], Jennifer K Meece[SUP] 2 [/SUP], Jessica E Biddle[SUP] 3 [/SUP], Natasha B Halasa[SUP] 1 [/SUP], Carrie Reed[SUP] 3 [/SUP], Alicia M Fry[SUP] 4 [/SUP], Yang Yang[SUP] 5 [/SUP], Edward A Belongia[SUP] 2 [/SUP], H Keipp Talbot[SUP] 1 [/SUP], Melissa A Rolfes[SUP] 3 [/SUP]



Affiliations
Free article Abstract

Importance: Influenza vaccine effectiveness (VE) is commonly assessed against prevention of illness that requires medical attention. Few studies have evaluated VE against secondary influenza infections.
Objective: To determine the estimated effectiveness of influenza vaccines in preventing secondary infections after influenza was introduced into households.
Design, settings, and participants: During 3 consecutive influenza seasons (2017-2020), primary cases (the first household members with laboratory-confirmed influenza) and their household contacts in Tennessee and Wisconsin were enrolled into a prospective case-ascertained household transmission cohort study. Participants collected daily symptom diaries and nasal swabs for up to 7 days. Data were analyzed from September 2022 to February 2024.
Exposures: Vaccination history, self-reported and verified through review of medical and registry records.
Main outcomes and measures: Specimens were tested using reverse transcription-polymerase chain reaction to determine influenza infection. Longitudinal chain binomial models were used to estimate secondary infection risk and the effectiveness of influenza vaccines in preventing infection among household contacts overall and by virus type and subtype and/or lineage.
Results: The analysis included 699 primary cases and 1581 household contacts. The median (IQR) age of the primary cases was 13 (7-38) years, 381 (54.5%) were female, 60 (8.6%) were Hispanic, 46 (6.6%) were non-Hispanic Black, 553 (79.1%) were Non-Hispanic White, and 343 (49.1%) were vaccinated. Among household contacts, the median age was 31 (10-41) years, 833 (52.7%) were female, 116 (7.3%) were Hispanic, 78 (4.9%) were non-Hispanic Black, 1283 (81.2%) were non-Hispanic White, 792 (50.1%) were vaccinated, and 356 (22.5%) had laboratory-confirmed influenza during follow-up. The overall secondary infection risk of influenza among household contacts was 18.8% (95% CI, 15.9% to 22.0%). The risk was highest among children and was 20.3% (95% CI, 16.4% to 24.9%) for influenza A and 15.9% (95% CI, 11.8% to 21.0%) for influenza B. The overall estimated VE for preventing secondary infections among unvaccinated household contacts was 21.0% (95% CI, 1.4% to 36.7%) and varied by type; estimated VE against influenza A was 5.0% (95% CI, -22.3% to 26.3%) and 56.4% (95% CI, 30.1% to 72.8%) against influenza B.
Conclusions and relevance: After influenza was introduced into households, the risk of secondary influenza among unvaccinated household contacts was approximately 15% to 20%, and highest among children. Estimated VE varied by influenza type, with demonstrated protection against influenza B virus infection.


 
Back
Top Bottom